- Q4 2023 CureVac NV Earnings Call TranscriptApr 24, 2024€2.27 (-4.70%)Earnings
- Q3 2023 CureVac NV Earnings Call TranscriptNov 14, 2023€5.35 (+6.79%)Earnings
- CureVac NV at Bank of America Global Healthcare Conference TranscriptMay 09, 2023
- Q4 2022 CureVac NV Earnings Call TranscriptApr 25, 2023€6.95 (-5.18%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptMar 28, 2023
- CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs TranscriptJan 06, 2023
- Q3 2022 CureVac NV Earnings Call TranscriptNov 16, 2022€7.89 (+2.04%)Earnings
- CureVac NV Annual Shareholders Meeting TranscriptJun 22, 2022
- CureVac NV at JMP Securities Life Sciences Conference TranscriptJun 15, 2022
- CureVac NV at Jefferies Healthcare Conference TranscriptJun 09, 2022
- CureVac NV at Bank of America Healthcare Conference TranscriptMay 10, 2022
- Q4 2021 CureVac NV Earnings Call TranscriptApr 28, 2022€15.2 (-1.05%)Earnings
- Q3 2021 CureVac NV Earnings Call TranscriptNov 19, 2021€36.83 (+4.54%)Earnings
- CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call TranscriptOct 12, 2021
- CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call TranscriptJul 01, 2021
- CureVac NV Updates On Clinical Trial - Corporate Call TranscriptJun 17, 2021
- Q4 2020 CureVac NV Earnings Call TranscriptApr 15, 2021€89 (+3.91%)Earnings
- CureVac N.V. - Special Call TranscriptFeb 05, 2021
CureVac NV Preliminary Phase 1 Data from Joint COVID-19 and Flu mRNA Vaccine Development Programs Transcript
Greetings. Welcome to CureVac's Preliminary Phase I Data from Joint COVID-19 and Flu mRNA Vaccine Development Program. This time all participant are in listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions). Please note this conference is being recorded. At this time, I'll now turn the conference over to Sarah Fakih, Vice President, Corporate Communications and Investor Relations. Ms. Fakih, you may now begin.
Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers. On the call with me from CureVac are Franz-Werner-Haas, our Chief Executive Officer; and Ulrike Gnad-Vogt, our Interim Chief Development Officer.
Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)